| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 153 | 2024 | 2781 | 24.930 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 166 | 2024 | 2525 | 22.770 |
Why?
|
| Protein Kinase Inhibitors | 183 | 2024 | 4768 | 13.630 |
Why?
|
| Fusion Proteins, bcr-abl | 92 | 2024 | 1093 | 11.480 |
Why?
|
| Antibodies, Bispecific | 30 | 2024 | 242 | 10.700 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 48 | 2024 | 505 | 10.380 |
Why?
|
| Philadelphia Chromosome | 57 | 2023 | 792 | 9.730 |
Why?
|
| Leukemia, Myeloid, Acute | 189 | 2024 | 6932 | 9.350 |
Why?
|
| Myelodysplastic Syndromes | 109 | 2024 | 2982 | 8.640 |
Why?
|
| Antineoplastic Agents | 165 | 2024 | 14288 | 8.590 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 27 | 2024 | 479 | 8.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 180 | 2023 | 15874 | 8.010 |
Why?
|
| Protein-Tyrosine Kinases | 57 | 2021 | 1759 | 7.260 |
Why?
|
| Pyrimidines | 104 | 2023 | 3538 | 7.000 |
Why?
|
| Azacitidine | 60 | 2023 | 1149 | 6.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 92 | 2024 | 6607 | 5.980 |
Why?
|
| Piperazines | 62 | 2015 | 2098 | 5.790 |
Why?
|
| Imatinib Mesylate | 87 | 2023 | 1665 | 5.590 |
Why?
|
| Pyridazines | 26 | 2024 | 292 | 5.430 |
Why?
|
| Dasatinib | 70 | 2023 | 862 | 5.350 |
Why?
|
| Drug Resistance, Neoplasm | 87 | 2024 | 5183 | 4.970 |
Why?
|
| Antineoplastic Agents, Immunological | 23 | 2021 | 1250 | 4.580 |
Why?
|
| Salvage Therapy | 47 | 2023 | 2059 | 4.520 |
Why?
|
| Cytarabine | 63 | 2023 | 1976 | 4.490 |
Why?
|
| Thiazoles | 42 | 2021 | 727 | 4.290 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2022 | 305 | 4.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 35 | 2022 | 3263 | 4.060 |
Why?
|
| Humans | 704 | 2024 | 262245 | 4.050 |
Why?
|
| Adult | 368 | 2024 | 78180 | 3.970 |
Why?
|
| Benzamides | 63 | 2015 | 1834 | 3.920 |
Why?
|
| Antimetabolites, Antineoplastic | 33 | 2018 | 1294 | 3.910 |
Why?
|
| Neoplasm, Residual | 45 | 2024 | 1668 | 3.770 |
Why?
|
| Vincristine | 37 | 2023 | 1508 | 3.750 |
Why?
|
| Remission Induction | 85 | 2024 | 3584 | 3.680 |
Why?
|
| Recurrence | 79 | 2024 | 4784 | 3.480 |
Why?
|
| Aged | 355 | 2024 | 70365 | 3.480 |
Why?
|
| Molecular Targeted Therapy | 28 | 2021 | 2334 | 3.450 |
Why?
|
| Treatment Outcome | 235 | 2024 | 33029 | 3.410 |
Why?
|
| Middle Aged | 382 | 2024 | 86544 | 3.310 |
Why?
|
| Disease-Free Survival | 105 | 2023 | 10021 | 3.230 |
Why?
|
| Imidazoles | 27 | 2024 | 1003 | 3.220 |
Why?
|
| Blast Crisis | 30 | 2023 | 557 | 3.060 |
Why?
|
| Aged, 80 and over | 223 | 2024 | 29996 | 3.040 |
Why?
|
| Arabinonucleosides | 21 | 2022 | 437 | 2.930 |
Why?
|
| Dexamethasone | 35 | 2023 | 1450 | 2.920 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 36 | 2024 | 923 | 2.870 |
Why?
|
| Doxorubicin | 31 | 2023 | 3005 | 2.730 |
Why?
|
| Prognosis | 143 | 2024 | 21736 | 2.680 |
Why?
|
| Young Adult | 156 | 2024 | 21494 | 2.650 |
Why?
|
| Hepatic Veno-Occlusive Disease | 6 | 2024 | 121 | 2.640 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 20 | 2024 | 426 | 2.590 |
Why?
|
| Mutation | 93 | 2023 | 15166 | 2.570 |
Why?
|
| Burkitt Lymphoma | 5 | 2023 | 334 | 2.460 |
Why?
|
| Adenine Nucleotides | 14 | 2017 | 351 | 2.460 |
Why?
|
| Idarubicin | 15 | 2023 | 446 | 2.440 |
Why?
|
| Cyclophosphamide | 36 | 2023 | 3080 | 2.390 |
Why?
|
| Male | 346 | 2024 | 123338 | 2.360 |
Why?
|
| Lymphoma, B-Cell | 7 | 2024 | 897 | 2.320 |
Why?
|
| Leukemia | 16 | 2022 | 1633 | 2.140 |
Why?
|
| Female | 341 | 2024 | 142290 | 2.130 |
Why?
|
| Sulfonamides | 36 | 2024 | 1826 | 2.080 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 20 | 2022 | 802 | 2.080 |
Why?
|
| Survival Rate | 79 | 2023 | 12239 | 2.060 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 10 | 2021 | 53 | 1.910 |
Why?
|
| Stem Cell Transplantation | 23 | 2023 | 1367 | 1.910 |
Why?
|
| Bone Marrow | 40 | 2021 | 2360 | 1.900 |
Why?
|
| Chromosome Aberrations | 23 | 2023 | 1957 | 1.870 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2024 | 10067 | 1.770 |
Why?
|
| Adolescent | 127 | 2022 | 31240 | 1.750 |
Why?
|
| Survival Analysis | 75 | 2021 | 9195 | 1.680 |
Why?
|
| Rituximab | 13 | 2022 | 1534 | 1.640 |
Why?
|
| Leukemia, Myeloid | 11 | 2022 | 941 | 1.640 |
Why?
|
| Acute Disease | 26 | 2024 | 2431 | 1.610 |
Why?
|
| Clinical Trials as Topic | 40 | 2022 | 3755 | 1.600 |
Why?
|
| Primary Myelofibrosis | 16 | 2021 | 831 | 1.460 |
Why?
|
| Kaplan-Meier Estimate | 50 | 2021 | 6223 | 1.450 |
Why?
|
| Cytogenetic Analysis | 17 | 2024 | 564 | 1.430 |
Why?
|
| Dose-Response Relationship, Drug | 36 | 2020 | 4945 | 1.420 |
Why?
|
| Retrospective Studies | 104 | 2024 | 38010 | 1.380 |
Why?
|
| Vidarabine | 15 | 2022 | 1347 | 1.350 |
Why?
|
| Age Factors | 41 | 2021 | 5384 | 1.330 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 6 | 2022 | 118 | 1.290 |
Why?
|
| Enzyme Inhibitors | 12 | 2021 | 1879 | 1.280 |
Why?
|
| Myeloproliferative Disorders | 11 | 2022 | 769 | 1.270 |
Why?
|
| Immunotherapy | 11 | 2022 | 3347 | 1.270 |
Why?
|
| Follow-Up Studies | 66 | 2023 | 14913 | 1.260 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2023 | 1765 | 1.250 |
Why?
|
| Drug Administration Schedule | 41 | 2020 | 3482 | 1.240 |
Why?
|
| Drug Monitoring | 9 | 2019 | 337 | 1.240 |
Why?
|
| Translocation, Genetic | 11 | 2021 | 1244 | 1.230 |
Why?
|
| Methotrexate | 15 | 2023 | 1002 | 1.230 |
Why?
|
| Neoplasm Proteins | 17 | 2021 | 3233 | 1.220 |
Why?
|
| Antigens, CD19 | 5 | 2023 | 579 | 1.150 |
Why?
|
| Hematologic Neoplasms | 14 | 2022 | 1901 | 1.120 |
Why?
|
| Treatment Failure | 19 | 2019 | 1392 | 1.110 |
Why?
|
| Transplantation, Homologous | 30 | 2023 | 2892 | 1.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2023 | 2393 | 1.100 |
Why?
|
| DNA Methylation | 26 | 2024 | 2671 | 1.060 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 4 | 2021 | 114 | 1.030 |
Why?
|
| Immunoconjugates | 5 | 2021 | 284 | 1.010 |
Why?
|
| Combined Modality Therapy | 28 | 2021 | 8886 | 1.000 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2020 | 560 | 0.990 |
Why?
|
| B-Lymphocytes | 5 | 2019 | 1306 | 0.990 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 2207 | 0.960 |
Why?
|
| Core Binding Factors | 5 | 2022 | 112 | 0.940 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2020 | 290 | 0.910 |
Why?
|
| Antibodies, Monoclonal | 11 | 2022 | 4385 | 0.900 |
Why?
|
| Graft vs Host Disease | 10 | 2024 | 2734 | 0.890 |
Why?
|
| Transplantation Conditioning | 10 | 2024 | 2286 | 0.870 |
Why?
|
| Chromosomes, Human, Pair 22 | 3 | 2020 | 170 | 0.870 |
Why?
|
| Induction Chemotherapy | 16 | 2023 | 665 | 0.860 |
Why?
|
| Leukemic Infiltration | 4 | 2020 | 72 | 0.850 |
Why?
|
| Pyrazoles | 15 | 2021 | 1479 | 0.840 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2024 | 197 | 0.840 |
Why?
|
| Propensity Score | 9 | 2022 | 755 | 0.830 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2020 | 79 | 0.830 |
Why?
|
| Medication Adherence | 6 | 2017 | 500 | 0.830 |
Why?
|
| Models, Economic | 2 | 2019 | 101 | 0.820 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2023 | 3549 | 0.790 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 1505 | 0.780 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 8 | 2017 | 111 | 0.770 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2023 | 2288 | 0.770 |
Why?
|
| Neoplasms, Second Primary | 10 | 2022 | 1350 | 0.770 |
Why?
|
| Drugs, Investigational | 4 | 2020 | 135 | 0.770 |
Why?
|
| Thalidomide | 7 | 2017 | 570 | 0.740 |
Why?
|
| Immunophenotyping | 13 | 2023 | 1684 | 0.740 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 596 | 0.740 |
Why?
|
| Flow Cytometry | 8 | 2019 | 3022 | 0.730 |
Why?
|
| Proportional Hazards Models | 20 | 2021 | 5009 | 0.730 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2021 | 454 | 0.720 |
Why?
|
| Disease Progression | 22 | 2021 | 6693 | 0.710 |
Why?
|
| Allografts | 9 | 2022 | 656 | 0.690 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 15 | 0.680 |
Why?
|
| Point Mutation | 5 | 2019 | 769 | 0.680 |
Why?
|
| Health Resources | 2 | 2018 | 168 | 0.680 |
Why?
|
| Isocitrate Dehydrogenase | 8 | 2023 | 483 | 0.680 |
Why?
|
| Quinolones | 3 | 2010 | 159 | 0.680 |
Why?
|
| Leukemia, B-Cell | 2 | 2017 | 116 | 0.670 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 224 | 0.660 |
Why?
|
| Drug Costs | 6 | 2020 | 145 | 0.660 |
Why?
|
| Antigens, CD | 2 | 2021 | 1382 | 0.660 |
Why?
|
| Asparaginase | 8 | 2021 | 184 | 0.650 |
Why?
|
| Iron Overload | 2 | 2009 | 34 | 0.650 |
Why?
|
| Drug Substitution | 4 | 2018 | 87 | 0.650 |
Why?
|
| Central Nervous System | 3 | 2022 | 440 | 0.640 |
Why?
|
| Drug Resistance | 2 | 2018 | 588 | 0.640 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2022 | 232 | 0.640 |
Why?
|
| Histone Deacetylase Inhibitors | 7 | 2023 | 612 | 0.630 |
Why?
|
| Retreatment | 15 | 2021 | 453 | 0.620 |
Why?
|
| Cladribine | 8 | 2023 | 233 | 0.620 |
Why?
|
| Farnesyltranstransferase | 6 | 2010 | 122 | 0.610 |
Why?
|
| Leukemia, Promyelocytic, Acute | 5 | 2021 | 429 | 0.610 |
Why?
|
| Erythrocyte Transfusion | 3 | 2018 | 211 | 0.600 |
Why?
|
| Disease Management | 13 | 2021 | 1063 | 0.600 |
Why?
|
| Nitriles | 15 | 2021 | 904 | 0.600 |
Why?
|
| Aniline Compounds | 6 | 2021 | 177 | 0.600 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2021 | 754 | 0.600 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2022 | 1041 | 0.600 |
Why?
|
| Janus Kinase 2 | 9 | 2019 | 680 | 0.590 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 1666 | 0.580 |
Why?
|
| Polymerase Chain Reaction | 6 | 2019 | 3189 | 0.570 |
Why?
|
| Risk Factors | 35 | 2020 | 17622 | 0.560 |
Why?
|
| Ipilimumab | 2 | 2018 | 719 | 0.560 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2023 | 3632 | 0.560 |
Why?
|
| Clinical Trials, Phase II as Topic | 10 | 2020 | 666 | 0.560 |
Why?
|
| Clonal Evolution | 6 | 2020 | 252 | 0.550 |
Why?
|
| Immunosuppressive Agents | 7 | 2018 | 1416 | 0.550 |
Why?
|
| Watchful Waiting | 1 | 2018 | 289 | 0.550 |
Why?
|
| Cohort Studies | 23 | 2023 | 9283 | 0.550 |
Why?
|
| Patient Safety | 3 | 2018 | 648 | 0.540 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 220 | 0.520 |
Why?
|
| Incidence | 14 | 2022 | 5713 | 0.520 |
Why?
|
| Health Care Costs | 2 | 2018 | 676 | 0.520 |
Why?
|
| Pandemics | 3 | 2022 | 1564 | 0.510 |
Why?
|
| Benzoates | 3 | 2021 | 133 | 0.510 |
Why?
|
| Polyethylene Glycols | 5 | 2018 | 621 | 0.510 |
Why?
|
| Withholding Treatment | 5 | 2024 | 162 | 0.510 |
Why?
|
| Biomarkers, Tumor | 15 | 2021 | 10348 | 0.490 |
Why?
|
| Drug Therapy, Combination | 11 | 2021 | 2325 | 0.490 |
Why?
|
| Nuclear Proteins | 10 | 2023 | 3317 | 0.490 |
Why?
|
| Prospective Studies | 25 | 2024 | 12923 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2020 | 2633 | 0.470 |
Why?
|
| Genes, p53 | 2 | 2017 | 1093 | 0.460 |
Why?
|
| Thrombocytosis | 3 | 2023 | 120 | 0.460 |
Why?
|
| Receptors, Cytokine | 5 | 2023 | 176 | 0.450 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2017 | 447 | 0.450 |
Why?
|
| Multivariate Analysis | 13 | 2021 | 4323 | 0.450 |
Why?
|
| Risk | 11 | 2021 | 1974 | 0.440 |
Why?
|
| Drug Evaluation, Preclinical | 6 | 2014 | 507 | 0.440 |
Why?
|
| Maintenance Chemotherapy | 5 | 2021 | 202 | 0.440 |
Why?
|
| Time Factors | 19 | 2021 | 12984 | 0.440 |
Why?
|
| Precision Medicine | 2 | 2019 | 1160 | 0.430 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 647 | 0.420 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 711 | 0.420 |
Why?
|
| Prednisone | 4 | 2021 | 983 | 0.410 |
Why?
|
| Thrombocytopenia | 9 | 2021 | 847 | 0.410 |
Why?
|
| Cell Lineage | 4 | 2024 | 663 | 0.410 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 4 | 2022 | 216 | 0.400 |
Why?
|
| DNA Mutational Analysis | 11 | 2020 | 2279 | 0.400 |
Why?
|
| Research Design | 4 | 2013 | 1562 | 0.390 |
Why?
|
| Interferon-alpha | 4 | 2012 | 889 | 0.390 |
Why?
|
| Drugs, Generic | 2 | 2022 | 35 | 0.390 |
Why?
|
| Patient Selection | 2 | 2018 | 2063 | 0.380 |
Why?
|
| Daunorubicin | 5 | 2023 | 302 | 0.380 |
Why?
|
| Anemia, Aplastic | 3 | 2018 | 218 | 0.370 |
Why?
|
| Mutation, Missense | 4 | 2019 | 1151 | 0.370 |
Why?
|
| Models, Biological | 5 | 2020 | 3242 | 0.370 |
Why?
|
| Monitoring, Physiologic | 5 | 2020 | 503 | 0.370 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2022 | 749 | 0.370 |
Why?
|
| Iron Chelating Agents | 2 | 2010 | 32 | 0.360 |
Why?
|
| Standard of Care | 3 | 2022 | 246 | 0.360 |
Why?
|
| Cytogenetics | 5 | 2013 | 149 | 0.360 |
Why?
|
| Genes, abl | 5 | 2019 | 110 | 0.350 |
Why?
|
| Nitrogen Mustard Compounds | 3 | 2015 | 73 | 0.350 |
Why?
|
| Benzimidazoles | 5 | 2020 | 428 | 0.350 |
Why?
|
| Animals | 23 | 2023 | 59487 | 0.350 |
Why?
|
| Triazoles | 2 | 2015 | 618 | 0.340 |
Why?
|
| Core Binding Factor beta Subunit | 2 | 2021 | 46 | 0.340 |
Why?
|
| Medical Oncology | 4 | 2012 | 1424 | 0.340 |
Why?
|
| Heart Diseases | 1 | 2015 | 738 | 0.340 |
Why?
|
| Quinolines | 4 | 2021 | 383 | 0.340 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 2 | 2020 | 106 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2023 | 1493 | 0.330 |
Why?
|
| Intention to Treat Analysis | 2 | 2019 | 130 | 0.330 |
Why?
|
| Biomarkers | 15 | 2020 | 5055 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2020 | 310 | 0.330 |
Why?
|
| In Situ Hybridization, Fluorescence | 9 | 2023 | 2232 | 0.320 |
Why?
|
| Comorbidity | 6 | 2019 | 2399 | 0.320 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2007 | 89 | 0.320 |
Why?
|
| Gene Rearrangement | 5 | 2024 | 784 | 0.320 |
Why?
|
| Neoplasms | 8 | 2023 | 15179 | 0.320 |
Why?
|
| Prodrugs | 3 | 2021 | 218 | 0.320 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 1684 | 0.320 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2020 | 1145 | 0.310 |
Why?
|
| Aminoglycosides | 6 | 2022 | 220 | 0.310 |
Why?
|
| Bone Marrow Examination | 3 | 2018 | 152 | 0.310 |
Why?
|
| T-Lymphocytes | 8 | 2023 | 3878 | 0.310 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2005 | 86 | 0.310 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 1690 | 0.310 |
Why?
|
| Protein Precursors | 3 | 2014 | 241 | 0.310 |
Why?
|
| Precursor Cells, T-Lymphoid | 3 | 2022 | 23 | 0.310 |
Why?
|
| Child | 28 | 2022 | 29067 | 0.300 |
Why?
|
| Alkylating Agents | 2 | 2024 | 78 | 0.300 |
Why?
|
| Maximum Tolerated Dose | 11 | 2021 | 1290 | 0.300 |
Why?
|
| Gallium Radioisotopes | 1 | 2007 | 60 | 0.300 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2017 | 505 | 0.300 |
Why?
|
| Meninges | 1 | 2007 | 46 | 0.290 |
Why?
|
| Antimetabolites | 2 | 2021 | 69 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2015 | 2362 | 0.290 |
Why?
|
| Proteomics | 4 | 2023 | 1386 | 0.290 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 1066 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2021 | 1247 | 0.280 |
Why?
|
| Arsenicals | 3 | 2021 | 201 | 0.280 |
Why?
|
| Therapies, Investigational | 2 | 2020 | 63 | 0.280 |
Why?
|
| Health Expenditures | 2 | 2019 | 211 | 0.280 |
Why?
|
| Antigens, CD20 | 2 | 2018 | 206 | 0.280 |
Why?
|
| Tandem Repeat Sequences | 4 | 2020 | 201 | 0.280 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2017 | 117 | 0.270 |
Why?
|
| Karyotyping | 6 | 2017 | 1017 | 0.270 |
Why?
|
| Severity of Illness Index | 11 | 2019 | 4355 | 0.270 |
Why?
|
| Administration, Oral | 9 | 2019 | 1554 | 0.270 |
Why?
|
| Anemia | 7 | 2019 | 690 | 0.260 |
Why?
|
| Germ-Line Mutation | 3 | 2020 | 1047 | 0.260 |
Why?
|
| Chronic Disease | 4 | 2024 | 1850 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2021 | 253 | 0.260 |
Why?
|
| Alleles | 4 | 2020 | 2434 | 0.250 |
Why?
|
| Chromosome Inversion | 3 | 2021 | 182 | 0.250 |
Why?
|
| Repressor Proteins | 6 | 2023 | 1663 | 0.250 |
Why?
|
| Antifungal Agents | 3 | 2022 | 840 | 0.250 |
Why?
|
| Risk Assessment | 12 | 2022 | 6900 | 0.250 |
Why?
|
| Piperidines | 7 | 2021 | 1053 | 0.250 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2023 | 106 | 0.250 |
Why?
|
| Gene Frequency | 4 | 2021 | 1165 | 0.250 |
Why?
|
| Hydrazines | 3 | 2021 | 208 | 0.250 |
Why?
|
| Age of Onset | 3 | 2019 | 826 | 0.240 |
Why?
|
| Calcitonin | 3 | 2014 | 186 | 0.240 |
Why?
|
| Diagnosis, Differential | 7 | 2018 | 4745 | 0.240 |
Why?
|
| Organophosphates | 3 | 2013 | 42 | 0.240 |
Why?
|
| Platelet Count | 5 | 2018 | 490 | 0.240 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 1338 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 544 | 0.240 |
Why?
|
| Injections, Spinal | 4 | 2019 | 257 | 0.240 |
Why?
|
| Uridine | 1 | 2024 | 59 | 0.230 |
Why?
|
| Thrombosis | 3 | 2019 | 786 | 0.230 |
Why?
|
| United States | 10 | 2023 | 15571 | 0.230 |
Why?
|
| Metaphase | 2 | 2017 | 106 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 4556 | 0.230 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 2 | 2020 | 63 | 0.220 |
Why?
|
| Mercaptopurine | 2 | 2021 | 128 | 0.220 |
Why?
|
| Dendritic Cells | 4 | 2022 | 1088 | 0.220 |
Why?
|
| Liposomes | 2 | 2020 | 680 | 0.220 |
Why?
|
| Marketing | 1 | 2022 | 18 | 0.220 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 623 | 0.220 |
Why?
|
| Hyperbilirubinemia | 3 | 2018 | 77 | 0.220 |
Why?
|
| Infusions, Intravenous | 7 | 2020 | 1379 | 0.220 |
Why?
|
| Adrenomedullin | 2 | 2014 | 105 | 0.220 |
Why?
|
| Hypoxia | 2 | 2016 | 448 | 0.220 |
Why?
|
| Genomics | 7 | 2023 | 2744 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2019 | 591 | 0.210 |
Why?
|
| Biomimetic Materials | 1 | 2022 | 41 | 0.210 |
Why?
|
| Neoplasm Staging | 10 | 2018 | 13669 | 0.210 |
Why?
|
| Naphthyridines | 3 | 2018 | 41 | 0.210 |
Why?
|
| Karyotype | 5 | 2022 | 234 | 0.210 |
Why?
|
| Eosinophilia | 1 | 2023 | 177 | 0.200 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1308 | 0.200 |
Why?
|
| L-Lactate Dehydrogenase | 4 | 2018 | 300 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 327 | 0.200 |
Why?
|
| Aurora Kinases | 3 | 2017 | 191 | 0.200 |
Why?
|
| Chromosomes, Human | 2 | 2017 | 292 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 1237 | 0.200 |
Why?
|
| Databases, Factual | 4 | 2015 | 2236 | 0.190 |
Why?
|
| Blood Transfusion | 3 | 2017 | 585 | 0.190 |
Why?
|
| Pyridines | 4 | 2021 | 1243 | 0.190 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 678 | 0.190 |
Why?
|
| Myosin Heavy Chains | 1 | 2021 | 129 | 0.190 |
Why?
|
| Valproic Acid | 3 | 2014 | 263 | 0.190 |
Why?
|
| Amino Acid Substitution | 3 | 2013 | 642 | 0.190 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Intracranial Hypertension | 1 | 2022 | 119 | 0.190 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
| Sarcoma, Myeloid | 1 | 2021 | 93 | 0.190 |
Why?
|
| Europe | 4 | 2018 | 646 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 125 | 0.190 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2020 | 45 | 0.190 |
Why?
|
| Leukocyte Count | 6 | 2021 | 683 | 0.180 |
Why?
|
| Transcriptome | 4 | 2023 | 1863 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2020 | 36 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Glycine | 3 | 2021 | 289 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 143 | 0.180 |
Why?
|
| Neutropenia | 8 | 2019 | 965 | 0.180 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 146 | 0.180 |
Why?
|
| Safety | 2 | 2018 | 464 | 0.180 |
Why?
|
| Janus Kinase 1 | 3 | 2018 | 122 | 0.180 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 53 | 0.180 |
Why?
|
| Sex Factors | 5 | 2019 | 2156 | 0.180 |
Why?
|
| Symptom Assessment | 2 | 2019 | 271 | 0.180 |
Why?
|
| Child, Preschool | 14 | 2022 | 16214 | 0.180 |
Why?
|
| Protein Structure, Tertiary | 4 | 2012 | 1487 | 0.180 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2020 | 304 | 0.170 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.170 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.170 |
Why?
|
| Immunoglobulins | 1 | 2020 | 266 | 0.170 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 72 | 0.170 |
Why?
|
| RNA, Messenger | 4 | 2016 | 6129 | 0.170 |
Why?
|
| Signal Transduction | 4 | 2021 | 11972 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2022 | 622 | 0.170 |
Why?
|
| DNA Modification Methylases | 2 | 2013 | 173 | 0.170 |
Why?
|
| Quinazolines | 3 | 2013 | 924 | 0.170 |
Why?
|
| Hydroxamic Acids | 2 | 2012 | 444 | 0.170 |
Why?
|
| Aminopyridines | 2 | 2021 | 213 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2021 | 2485 | 0.170 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2019 | 83 | 0.170 |
Why?
|
| Costs and Cost Analysis | 2 | 2017 | 305 | 0.170 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 90 | 0.170 |
Why?
|
| Optic Neuritis | 1 | 2019 | 39 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2020 | 591 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 5 | 2020 | 154 | 0.170 |
Why?
|
| Carbolines | 1 | 2018 | 27 | 0.160 |
Why?
|
| Reimbursement, Incentive | 1 | 2019 | 53 | 0.160 |
Why?
|
| Nitroimidazoles | 2 | 2016 | 100 | 0.160 |
Why?
|
| Forecasting | 2 | 2020 | 695 | 0.160 |
Why?
|
| Pyrimidinones | 2 | 2022 | 315 | 0.160 |
Why?
|
| Peroxidase | 1 | 2019 | 133 | 0.160 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 140 | 0.160 |
Why?
|
| Tretinoin | 4 | 2021 | 622 | 0.160 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2018 | 57 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 1435 | 0.160 |
Why?
|
| Etoposide | 2 | 2018 | 873 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2019 | 91 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 2182 | 0.160 |
Why?
|
| Pyridones | 2 | 2022 | 350 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 148 | 0.160 |
Why?
|
| Phosphoproteins | 2 | 2021 | 1151 | 0.160 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 52 | 0.160 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 51 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 474 | 0.160 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 50 | 0.160 |
Why?
|
| Chromosome Deletion | 3 | 2022 | 1002 | 0.160 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 92 | 0.160 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 184 | 0.150 |
Why?
|
| Harringtonines | 2 | 2017 | 92 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 5538 | 0.150 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 121 | 0.150 |
Why?
|
| Vitamin B Complex | 1 | 2018 | 51 | 0.150 |
Why?
|
| Deoxyadenosines | 1 | 2017 | 42 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 2420 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 223 | 0.150 |
Why?
|
| Sulfones | 2 | 2016 | 143 | 0.150 |
Why?
|
| Income | 3 | 2023 | 225 | 0.150 |
Why?
|
| Stem Cells | 2 | 2022 | 1206 | 0.150 |
Why?
|
| Lymphoma | 2 | 2017 | 1471 | 0.150 |
Why?
|
| Carnitine | 1 | 2018 | 93 | 0.150 |
Why?
|
| Genes, ras | 2 | 2022 | 667 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 257 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 248 | 0.150 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 37 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2018 | 367 | 0.150 |
Why?
|
| Exotoxins | 1 | 2017 | 77 | 0.150 |
Why?
|
| Linear Models | 2 | 2017 | 1091 | 0.150 |
Why?
|
| Bortezomib | 1 | 2019 | 544 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 638 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 673 | 0.150 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 311 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2018 | 431 | 0.140 |
Why?
|
| Yttrium Radioisotopes | 1 | 2018 | 178 | 0.140 |
Why?
|
| Hydrolases | 1 | 2017 | 123 | 0.140 |
Why?
|
| Abnormal Karyotype | 1 | 2017 | 100 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 389 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2018 | 413 | 0.140 |
Why?
|
| Fatigue | 7 | 2019 | 1239 | 0.140 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 447 | 0.140 |
Why?
|
| Kidney | 3 | 2019 | 2144 | 0.140 |
Why?
|
| DNA, Neoplasm | 3 | 2018 | 1905 | 0.140 |
Why?
|
| Injections, Intravenous | 2 | 2015 | 576 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 740 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 390 | 0.140 |
Why?
|
| Anthracyclines | 2 | 2010 | 331 | 0.140 |
Why?
|
| Lymphocyte Transfusion | 1 | 2017 | 178 | 0.140 |
Why?
|
| Phosphoramide Mustards | 1 | 2016 | 37 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 591 | 0.140 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 89 | 0.140 |
Why?
|
| Cause of Death | 3 | 2021 | 757 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 277 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 454 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 3 | 2020 | 2480 | 0.140 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 69 | 0.140 |
Why?
|
| Gene Expression | 4 | 2019 | 3563 | 0.140 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 696 | 0.140 |
Why?
|
| Gene Order | 1 | 2016 | 111 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2016 | 773 | 0.130 |
Why?
|
| Half-Life | 1 | 2016 | 258 | 0.130 |
Why?
|
| Hematopoiesis | 1 | 2019 | 562 | 0.130 |
Why?
|
| Autografts | 3 | 2023 | 166 | 0.130 |
Why?
|
| Maytansine | 1 | 2015 | 38 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 228 | 0.130 |
Why?
|
| Mastocytosis, Systemic | 1 | 2016 | 110 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2018 | 483 | 0.130 |
Why?
|
| Antilymphocyte Serum | 2 | 2017 | 230 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 72 | 0.130 |
Why?
|
| Immunotoxins | 1 | 2015 | 117 | 0.130 |
Why?
|
| Quality of Life | 5 | 2022 | 4582 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 253 | 0.130 |
Why?
|
| Iron | 2 | 2009 | 377 | 0.130 |
Why?
|
| Interferon-beta | 1 | 2015 | 102 | 0.130 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 882 | 0.130 |
Why?
|
| Pilot Projects | 6 | 2019 | 2803 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 73 | 0.130 |
Why?
|
| Thymoma | 1 | 2018 | 247 | 0.130 |
Why?
|
| Morpholines | 1 | 2016 | 289 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 524 | 0.130 |
Why?
|
| Biopsy | 6 | 2018 | 3447 | 0.130 |
Why?
|
| Mast Cells | 1 | 2016 | 222 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 869 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 760 | 0.130 |
Why?
|
| Cytosine | 2 | 2012 | 141 | 0.130 |
Why?
|
| Hydroxyurea | 3 | 2022 | 204 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 1826 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2017 | 2325 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 4903 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 24 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 445 | 0.120 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 78 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 481 | 0.120 |
Why?
|
| ras Proteins | 3 | 2022 | 771 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 720 | 0.120 |
Why?
|
| RNA Splicing Factors | 3 | 2021 | 153 | 0.120 |
Why?
|
| World Health Organization | 3 | 2022 | 315 | 0.120 |
Why?
|
| Dioxygenases | 3 | 2021 | 160 | 0.120 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 1397 | 0.120 |
Why?
|
| Catalytic Domain | 2 | 2014 | 305 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 402 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 327 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 856 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 333 | 0.110 |
Why?
|
| Adenine | 3 | 2021 | 639 | 0.110 |
Why?
|
| Urea | 1 | 2014 | 288 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2019 | 1360 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2015 | 256 | 0.110 |
Why?
|
| Liver Diseases | 2 | 2015 | 570 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4655 | 0.110 |
Why?
|
| Ferritins | 2 | 2014 | 152 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 588 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1230 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 148 | 0.110 |
Why?
|
| Febrile Neutropenia | 3 | 2018 | 67 | 0.110 |
Why?
|
| Lymphocyte Count | 3 | 2019 | 488 | 0.110 |
Why?
|
| Indazoles | 1 | 2014 | 299 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2016 | 605 | 0.110 |
Why?
|
| Polycythemia Vera | 1 | 2015 | 238 | 0.110 |
Why?
|
| Clone Cells | 2 | 2011 | 547 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 210 | 0.110 |
Why?
|
| Fever of Unknown Origin | 1 | 2013 | 61 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2012 | 64 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 907 | 0.110 |
Why?
|
| Patient Care | 1 | 2013 | 149 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 802 | 0.110 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 334 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 44 | 0.100 |
Why?
|
| Apoptosis | 6 | 2022 | 7601 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 603 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 848 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2012 | 72 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 189 | 0.100 |
Why?
|
| Patient Compliance | 2 | 2017 | 671 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2017 | 1440 | 0.100 |
Why?
|
| Sepsis | 2 | 2014 | 657 | 0.100 |
Why?
|
| Melphalan | 3 | 2019 | 834 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1221 | 0.100 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 182 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 603 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2014 | 425 | 0.100 |
Why?
|
| Mycoses | 1 | 2015 | 386 | 0.100 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 274 | 0.100 |
Why?
|
| Survivors | 2 | 2014 | 1035 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 640 | 0.100 |
Why?
|
| Professional Role | 1 | 2012 | 76 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2012 | 193 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 526 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4980 | 0.100 |
Why?
|
| Antineoplastic Protocols | 1 | 2011 | 33 | 0.100 |
Why?
|
| Algorithms | 3 | 2011 | 3889 | 0.100 |
Why?
|
| Cyclosporine | 1 | 2012 | 282 | 0.100 |
Why?
|
| Prevalence | 2 | 2016 | 3272 | 0.100 |
Why?
|
| Bone Marrow Diseases | 1 | 2012 | 174 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 14560 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2013 | 223 | 0.090 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 128 | 0.090 |
Why?
|
| Texas | 2 | 2020 | 6308 | 0.090 |
Why?
|
| Liver | 2 | 2017 | 2904 | 0.090 |
Why?
|
| Logistic Models | 2 | 2017 | 3450 | 0.090 |
Why?
|
| Benzothiazoles | 2 | 2021 | 94 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 121 | 0.090 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2010 | 31 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 758 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6046 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 692 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 34 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 1439 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 730 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 4 | 2018 | 587 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 1083 | 0.090 |
Why?
|
| Bone Marrow Cells | 3 | 2018 | 939 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2015 | 1227 | 0.090 |
Why?
|
| Time | 2 | 2020 | 179 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2014 | 899 | 0.090 |
Why?
|
| Staurosporine | 2 | 2020 | 142 | 0.090 |
Why?
|
| Constipation | 2 | 2021 | 178 | 0.090 |
Why?
|
| Spain | 1 | 2009 | 113 | 0.090 |
Why?
|
| Hospitals, Public | 1 | 2009 | 64 | 0.090 |
Why?
|
| Fever | 1 | 2012 | 499 | 0.080 |
Why?
|
| Molecular Structure | 2 | 2007 | 524 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2009 | 133 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 447 | 0.080 |
Why?
|
| Graft Survival | 2 | 2018 | 1072 | 0.080 |
Why?
|
| ROC Curve | 3 | 2020 | 1181 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2014 | 451 | 0.080 |
Why?
|
| Oxides | 2 | 2021 | 211 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 7545 | 0.080 |
Why?
|
| Calcitonin Gene-Related Peptide | 3 | 2014 | 162 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2018 | 787 | 0.080 |
Why?
|
| Carmustine | 2 | 2019 | 214 | 0.080 |
Why?
|
| Terminal Care | 1 | 2013 | 446 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 968 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2012 | 478 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 491 | 0.080 |
Why?
|
| Cranial Irradiation | 1 | 2010 | 316 | 0.080 |
Why?
|
| Transplantation, Autologous | 3 | 2021 | 1925 | 0.080 |
Why?
|
| Drug Utilization | 1 | 2009 | 180 | 0.080 |
Why?
|
| SEER Program | 2 | 2021 | 1000 | 0.080 |
Why?
|
| Polyradiculopathy | 1 | 2007 | 13 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 474 | 0.070 |
Why?
|
| Infant | 5 | 2022 | 13286 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 321 | 0.070 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 581 | 0.070 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 247 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 479 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 510 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1827 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2014 | 1234 | 0.070 |
Why?
|
| Consensus | 2 | 2022 | 1005 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 541 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2062 | 0.070 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2006 | 74 | 0.070 |
Why?
|
| Meningitis | 1 | 2007 | 112 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2023 | 715 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2008 | 442 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2302 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 443 | 0.070 |
Why?
|
| Papilledema | 1 | 2007 | 85 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2020 | 6104 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 804 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 575 | 0.070 |
Why?
|
| Encephalitis | 1 | 2007 | 142 | 0.070 |
Why?
|
| Phenotype | 3 | 2023 | 6255 | 0.070 |
Why?
|
| Bilirubin | 2 | 2018 | 221 | 0.060 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 45 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 935 | 0.060 |
Why?
|
| Serum Albumin | 2 | 2019 | 251 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2021 | 1991 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 2915 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2006 | 203 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 1040 | 0.060 |
Why?
|
| Exanthema | 2 | 2019 | 210 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 2969 | 0.060 |
Why?
|
| Growth Substances | 1 | 2005 | 298 | 0.060 |
Why?
|
| Probability | 3 | 2012 | 868 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 246 | 0.060 |
Why?
|
| Interferon Type I | 1 | 2005 | 250 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2008 | 834 | 0.060 |
Why?
|
| Camptothecin | 1 | 2006 | 515 | 0.060 |
Why?
|
| Mice | 5 | 2023 | 34391 | 0.060 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 4787 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Stomatitis | 2 | 2016 | 183 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2023 | 111 | 0.060 |
Why?
|
| Drug Design | 1 | 2006 | 379 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2004 | 171 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1448 | 0.060 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2014 | 108 | 0.060 |
Why?
|
| Spleen | 2 | 2015 | 674 | 0.060 |
Why?
|
| Receptors, Complement 3b | 1 | 2022 | 20 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2151 | 0.050 |
Why?
|
| Pol1 Transcription Initiation Complex Proteins | 1 | 2022 | 11 | 0.050 |
Why?
|
| CDX2 Transcription Factor | 1 | 2022 | 38 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3891 | 0.050 |
Why?
|
| Aurora Kinase B | 2 | 2013 | 68 | 0.050 |
Why?
|
| Nausea | 2 | 2015 | 525 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 58 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2022 | 366 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 48 | 0.050 |
Why?
|
| Pneumonia | 2 | 2021 | 754 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 254 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2021 | 88 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 699 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2021 | 1740 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 100 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2014 | 477 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2021 | 165 | 0.050 |
Why?
|
| Seizures | 1 | 2007 | 986 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 217 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 36 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 95 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 11571 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8882 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2020 | 424 | 0.050 |
Why?
|
| Premedication | 1 | 2020 | 134 | 0.050 |
Why?
|
| Triazines | 1 | 2021 | 117 | 0.050 |
Why?
|
| Glutamine | 1 | 2022 | 300 | 0.050 |
Why?
|
| IMP Dehydrogenase | 1 | 2020 | 28 | 0.050 |
Why?
|
| Thrombopoietin | 2 | 2010 | 77 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 1435 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 372 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 109 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 50 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 425 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 496 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 265 | 0.040 |
Why?
|
| Carbazoles | 1 | 2020 | 87 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2019 | 101 | 0.040 |
Why?
|
| Furans | 1 | 2020 | 106 | 0.040 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 744 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 703 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3983 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 63 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 88 | 0.040 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2019 | 31 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 67 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 80 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2023 | 5253 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 346 | 0.040 |
Why?
|
| Diploidy | 1 | 2018 | 112 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2020 | 253 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 809 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2312 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 338 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 904 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 734 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 322 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 289 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 28 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 104 | 0.040 |
Why?
|
| Acetylation | 2 | 2011 | 511 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 137 | 0.040 |
Why?
|
| Survival | 1 | 2018 | 177 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 339 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 984 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2017 | 83 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2021 | 628 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 501 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 671 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8225 | 0.040 |
Why?
|
| Adolescent Development | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 474 | 0.040 |
Why?
|
| Pyrazines | 1 | 2020 | 495 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 834 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 548 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 950 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2018 | 174 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 571 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 526 | 0.040 |
Why?
|
| Homocysteine | 1 | 2017 | 137 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 384 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 645 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 1111 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 948 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 340 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 333 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 992 | 0.030 |
Why?
|
| Trisomy | 1 | 2017 | 230 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2019 | 842 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 393 | 0.030 |
Why?
|
| Cytokines | 1 | 2005 | 2823 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 173 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 26 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 503 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1514 | 0.030 |
Why?
|
| Vomiting | 2 | 2007 | 352 | 0.030 |
Why?
|
| Itraconazole | 1 | 2015 | 77 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 242 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 194 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 65 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 36 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 44 | 0.030 |
Why?
|
| Calreticulin | 1 | 2015 | 75 | 0.030 |
Why?
|
| Esophagitis | 1 | 2016 | 202 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 251 | 0.030 |
Why?
|
| Dizziness | 1 | 2015 | 47 | 0.030 |
Why?
|
| Fertility Preservation | 1 | 2017 | 150 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 312 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2015 | 55 | 0.030 |
Why?
|
| Dyspnea | 1 | 2018 | 417 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 263 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 232 | 0.030 |
Why?
|
| Enterocolitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1316 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 2053 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 76 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 68 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 658 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 257 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 604 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 349 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 147 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 5155 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1024 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2015 | 289 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 1595 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 654 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 130 | 0.030 |
Why?
|
| U937 Cells | 1 | 2014 | 172 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 823 | 0.030 |
Why?
|
| Pruritus | 1 | 2014 | 87 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 839 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2014 | 302 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 593 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 1884 | 0.030 |
Why?
|
| Family | 1 | 2017 | 735 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 699 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 538 | 0.030 |
Why?
|
| China | 1 | 2014 | 613 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 385 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 410 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 189 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 467 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 621 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2014 | 319 | 0.030 |
Why?
|
| Terminally Ill | 1 | 2013 | 91 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 882 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2014 | 389 | 0.030 |
Why?
|
| Histones | 2 | 2011 | 1462 | 0.030 |
Why?
|
| Aspirin | 1 | 2015 | 455 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 723 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 332 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2011 | 254 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5071 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 258 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2011 | 198 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 704 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2014 | 398 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 225 | 0.020 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2012 | 181 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1958 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 259 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2010 | 68 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 15709 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 724 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 4231 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 2605 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 217 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 364 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 4886 | 0.020 |
Why?
|
| Critical Illness | 1 | 2014 | 717 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2008 | 72 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2008 | 64 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2008 | 105 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 928 | 0.020 |
Why?
|
| Bacteremia | 1 | 2014 | 689 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 6062 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2009 | 108 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1541 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2012 | 637 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 2085 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 874 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 253 | 0.020 |
Why?
|
| Mastectomy | 1 | 2014 | 1538 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7549 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 3438 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 788 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 2119 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 1011 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 68 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 78 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2007 | 259 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1947 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 186 | 0.020 |
Why?
|
| Drug Approval | 1 | 2006 | 178 | 0.020 |
Why?
|
| North America | 1 | 2005 | 313 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 1557 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4043 | 0.020 |
Why?
|
| Neutrophils | 1 | 2008 | 834 | 0.010 |
Why?
|
| Diarrhea | 1 | 2007 | 689 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4838 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 706 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2006 | 637 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7241 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5124 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 4976 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7717 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 2992 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 1870 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 2683 | 0.010 |
Why?
|